Daunorubicin/cytarabine

Daunorubicin/cytarabine
Cytarabine
daunorubicin
Combination of
CytarabineAntimetabolite
DaunorubicinAnthracycline
Names
Trade namesVyxeos, Vyxeos liposomal
Clinical data
Main usesAcute myeloid leukemia (AML)[1]
Side effectsBleeding, low neutrophils, rash, swelling, nausea, diarrhea, tiredness, cough, arrhythmias, sepsis[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • US: N (Not classified yet)
    Routes of
    use    		Intravenous
    External links
    AHFS/Drugs.comMonograph
    Legal
    License data
    Legal status

    Daunorubicin/cytarabine is a combination medicine used to treat acute myeloid leukemia (AML).[1] Specifically it is used for therapy related disease (t-AML) or AML with myelodysplasia-related changes (AML-MRC).[1] It is given by a central venous line.[2] The combination differs from the individual components.[2]

    Common side effects include bleeding, low neutrophils, rash, swelling, nausea, diarrhea, tiredness, cough, arrhythmias, and sepsis.[1] Other side effects may include heart toxicity, anaphylaxis, and tissue necrosis.[1] Use in pregnancy may harm the baby.[1] Daunorubicin is an anthracycline topoisomerase inhibitor while cytarabine is a nucleoside metabolic inhibitor.[1] These are contained with liposomes.[1]

    The combination was approved for medical use in the United States in 2017 and Europe in 2018.[1][3] In the United Kingdom a vial of 44 mg daunorubicin/100 mg cytarabine costs the NHS about £4,600 as of 2021.[4] This amount in the United States costs about 9,300 USD.[5]

    References

    1. 1 2 3 4 5 6 7 8 9 10 "DailyMed - VYXEOS (- daunorubicin and cytarabine liposome injection, powder, lyophilized, for suspension". dailymed.nlm.nih.gov. Archived from the original on 29 March 2021. Retrieved 21 December 2021.
    2. 1 2 "DAUNOrubicin and Cytarabine Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 21 December 2021.
    3. ↑ "Vyxeos liposomal (previously known as Vyxeos)". Archived from the original on 6 May 2021. Retrieved 21 December 2021.
    4. ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 945. ISBN 978-0857114105.
    5. ↑ "Vyxeos Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 18 April 2021. Retrieved 21 December 2021.
    Identifiers:
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.